FDA updates Repros on Proellex clinical hold
01 October 2009
Katie McQue
Please Login to read the full article.
01 October 2009
Katie McQue
katie.mcque@informa.com
The US
FDA has provided Repros Therapeutics with further clarification over the full clinical hold status of its lead drug, the orally selective progesterone antagonist Proellex, and guidance for the company to get the hold lifted. The drug was being looked at for the treatment of chronic symptomatic...
Please Login to read the full article.
RELATED CONTENT
NEWS
- YM BioSciences rises on PhI/II results showing promise for JAK1/JAK2 inhibitor for myelofibrosis
- ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem
- Idenix plunges on clinical hold, despite another being lifted
- France votes for more regulatory transparency, tighter safety monitoring and tougher promotion controls
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
